Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,339 result(s) found. Displaying page 1,068 of 2,217.
    EudraCT Number: 2014-004787-37 Sponsor Protocol Number: VX14-661-107 Start Date*: 2015-09-21
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cy...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004545-27 Sponsor Protocol Number: GS-US-366-1216 Start Date*: 2015-06-16
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positiv...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005882-19 Sponsor Protocol Number: 109995 Start Date*: 2015-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Prio...
    Medical condition: Measles, mumps, rubella and varicella diseases
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002228-34 Sponsor Protocol Number: 2012/1vas Start Date*: 2015-09-30
    Sponsor Name:Diego Caicedo Valdés
    Full Title: Growth hormone (GH) angiogenic effect clinical trial on patients with lower limb critical ischemia. GHAS Study
    Medical condition: Lower limb critical ischemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10023034 Ischemia peripheral LLT
    18.0 100000004866 10058069 Critical limb ischemia LLT
    18.0 100000004866 10066920 Leg ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000584-14 Sponsor Protocol Number: AGLU03807,MSC12862 Start Date*: 2015-04-15
    Sponsor Name:Genzyme Corporation Inc
    Full Title: An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease
    Medical condition: Pompe disease (acid alpha-glucosidase deficiency)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10036143 Pompe's disease LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004175-23 Sponsor Protocol Number: A9451165 Start Date*: 2015-04-07
    Sponsor Name:Pfizer Japan Inc
    Full Title: A 52 weeks, open-label, multicenter study evaluating the efficacy and safety of gabapentin as adjunctive therapy in pediatric subjects who have completed the 12 weeks treatment in study A9451162.
    Medical condition: Epilepsy with partial seizures (including secondarily generalized seizures)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004964-39 Sponsor Protocol Number: 51503 Start Date*: 2015-05-22
    Sponsor Name:Sint Antonius Ziekenhuis
    Full Title: Clonidine as Additive for Locoregional Postoperative Analgesia in Foot and Anckle Surgery
    Medical condition: Postoperative pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001704-22 Sponsor Protocol Number: CCD-05993AA1-08 Start Date*: 2015-02-25
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formote...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PT (Completed) HU (Completed) CZ (Completed) RO (Completed) DK (Completed) DE (Completed) AT (Completed) NO (Completed) PL (Completed) FR (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005026-35 Sponsor Protocol Number: 35RC14_9853_DEXA-OP Start Date*: Information not available in EudraCT
    Sponsor Name:Centre Hospitalier Universitaire de Rennes
    Full Title: Study DEXA-OP. Can the dexaméthasone replace the kétoprofène in the strategy of per-operating multimodal analgesia in pediatric ambulatory surgery? A double-blind randomized comparative study.
    Medical condition: Per-operating analgesia, pediatric ambulatory surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10002321 Anesthesia LLT
    18.0 10042613 - Surgical and medical procedures 10042609 Surgery PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001216-35 Sponsor Protocol Number: CONCERTAATT4086 Start Date*: 2015-04-24
    Sponsor Name:Johnson & Johnson Taiwan Ltd
    Full Title: From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002328-34 Sponsor Protocol Number: KB056 Start Date*: Information not available in EudraCT
    Sponsor Name:KEDRION S.P.A
    Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont...
    Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10067439 Haemostasis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001218-92 Sponsor Protocol Number: CON-KOR-012 Start Date*: 2015-04-24
    Sponsor Name:Janssen Korea Ltd
    Full Title: A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005387-25 Sponsor Protocol Number: noprofit1616 Start Date*: 2016-05-05
    Sponsor Name:Sapienza, University of Rome
    Full Title: Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy
    Medical condition: Glioblastoma is the most common primary brain tumour in humans with the most severe prognosis. Standard treatments consist primarily of surgery in order to debulk thetumoral mass, as well as radioc...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10045172 Tumour vaccine therapies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001076-22 Sponsor Protocol Number: 03-0-160 Start Date*: 2015-04-13
    Sponsor Name:Fujisawa Healthcare, Inc.
    Full Title: A PHASE II, OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS THE PHARMACOKINETICS, LONG-TERM SAFETY AND TOLERABILITY OF TACROLIMUS IN STABLE PEDIATRIC LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF® BA...
    Medical condition: Liver transplant rejection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10050434 Prophylaxis against liver transplant rejection LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001041-83 Sponsor Protocol Number: FKC-009 Start Date*: 2015-04-13
    Sponsor Name:Astellas Pharma Canada Inc.
    Full Title: Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Im...
    Medical condition: Cardiac transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004464-38 Sponsor Protocol Number: 20120296 Start Date*: 2015-06-25
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Medical condition: Migraine Prevention
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) CZ (Completed) DE (Completed) SK (Completed) AT (Completed) PL (Completed) HU (Prematurely Ended) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003267-55 Sponsor Protocol Number: A3L45 Start Date*: 2015-09-03
    Sponsor Name:Sanofi Pasteur SA
    Full Title: An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland.
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001696-51 Sponsor Protocol Number: 25735 Start Date*: 2015-07-15
    Sponsor Name:Merck KGaA [...]
    1. Merck KGaA
    2. Merck Serono s.a.s.
    Full Title: Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Eff...
    Medical condition: Small for Gestational Age (SGA)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002895-26 Sponsor Protocol Number: PrEP-CS-001 Start Date*: 2015-09-08
    Sponsor Name:hVIVO Services Limited
    Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In...
    Medical condition: Influenza A/Perth/16/2009(H3N2) Virus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005635-14 Sponsor Protocol Number: BUX-3/UCA Start Date*: 2015-06-08
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative c...
    Medical condition: Patients with active ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 21:58:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA